{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:58:17Z","timestamp":1792785497318,"version":"4.5.0"},"reference-count":99,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Neurelis","id":[{"id":"https:\/\/ror.org\/0358t2s53","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Delivery"],"published-print":{"date-parts":[[2026,10,3]]},"DOI":"10.1080\/17425247.2026.2713668","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:12:56Z","timestamp":1786367576000},"page":"1863-1875","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Clinical insights: an update on transmucosal absorption with a focus on dodecyl maltoside"],"prefix":"10.1080","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-0606","authenticated-orcid":false,"given":"Adrian L.","family":"Rabinowicz","sequence":"first","affiliation":[{"name":"Neurelis, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Madden","sequence":"additional","affiliation":[{"name":"Neurelis, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Carrazana","sequence":"additional","affiliation":[{"name":"Neurelis, Inc., San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2206568"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16847"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14479"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567201819666220401091632"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1978245600"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11010033"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.23nr03596"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12905"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.256115"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16449"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-819712-7.00015-2"},{"key":"e_1_3_5_14_1","unstructured":"US Food and Drug Administration. Clinical superiority findings. 2024 [cited 2025 Jul 3]. Available from: https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/clinical-superiority-findings"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.108013"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081754"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-023-00601-x"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2024.100644"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15082119"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebr.2022.100581"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2011.11.002"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125584"},{"key":"e_1_3_5_23_1","first-page":"657","volume-title":"Aulton\u2019s pharmaceutics: the design and manufacture of medicines","author":"Martin GP","year":"2013","unstructured":"Martin GP, Lansley AB. Nasal drug delivery. In: Taylor KM Aulton ME, editors. Aulton\u2019s pharmaceutics: the design and manufacture of medicines. 4th ed. London (UK): Churchill Livingstone; 2013. p. 657\u2013674.","edition":"4"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720112803529828"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.07.030"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-021-00360-5"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2017.12.025"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2008.09.016"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11030113"},{"key":"e_1_3_5_30_1","first-page":"100","article-title":"Absorption enhancing excipients in systemic nasal drug delivery","volume":"5","author":"Maggio ET","year":"2014","unstructured":"Maggio ET. Absorption enhancing excipients in systemic nasal drug delivery. J Excipients Food Chem. 2014;5:100\u2013112.","journal-title":"J Excipients Food Chem"},{"issue":"883","key":"e_1_3_5_31_1","first-page":"728 B2","article-title":"Intranasal administration of active agents to the central nervous system","volume":"8","author":"Maggio ET","year":"2014","unstructured":"Maggio ET. Intranasal administration of active agents to the central nervous system. US. 2014;8(883):728 B2.","journal-title":"US"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/polym15071615"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02974-9"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17091180"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-012-0069-z"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11070339"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2025.106623"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.15171\/apb.2019.023"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.102156"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2022.04.015"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2022.07.007"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajps.2014.09.004"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2273.1999.00223.x"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221330"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1994.tb02051.x"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05005.x"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.4898"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12755"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40005-020-00482-z"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.18473"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.12.051"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-019-0118-0"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061720"},{"key":"e_1_3_5_54_1","unstructured":"US Food & Drug Administration. FDA approves first over-the-counter naloxone nasal spray [press release]. 2023 [cited 2023 Jul 14]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-over-counter-naloxone-nasal-spray"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7253.83"},{"key":"e_1_3_5_56_1","volume-title":"IMITREX\u00ae (sumatriptan). Full prescribing information","author":"GlaxoSmithKline","year":"2021","unstructured":"GlaxoSmithKline. IMITREX\u00ae (sumatriptan). Full prescribing information. Research Triangle Park (NC): GlaxoSmithKline LLC; 2021."},{"key":"e_1_3_5_57_1","volume-title":"Naloxone hydrochloride injection full prescribing information","author":"Kaleo, Inc","year":"2022","unstructured":"Kaleo, Inc. Naloxone hydrochloride injection full prescribing information. Richmond (VA): Kaleo, Inc; 2022."},{"key":"e_1_3_5_58_1","unstructured":"Center for Drug Evaluation and Research. Summary review of regulatory action. 2011 [cited 2025 May 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/201739Orig1s000MedR.pdf"},{"key":"e_1_3_5_59_1","unstructured":"US Food & Drug Administration. FDA approves first nasal spray for treatment of anaphylaxis. 2024 [cited 2025 Jul 18]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-nasal-spray-treatment-anaphylaxis"},{"key":"e_1_3_5_60_1","volume-title":"VALTOCO\u00ae (diazepam nasal spray). Full prescribing information","author":"Neurelis, Inc","year":"2025","unstructured":"Neurelis, Inc. VALTOCO\u00ae (diazepam nasal spray). Full prescribing information. San Diego (CA): Neurelis, Inc.; 2025."},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107898"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.04.007"},{"key":"e_1_3_5_63_1","volume-title":"OPVEE (nalmefene nasal spray). Full prescribing information","author":"Indivior Inc","year":"2023","unstructured":"Indivior Inc. OPVEE (nalmefene nasal spray). Full prescribing information. North Chesterfield (VA): Indivior Inc; 2023."},{"key":"e_1_3_5_64_1","volume-title":"TOSYMRA\u00ae (sumatriptan). Full Prescribing Information","author":"Tonix Pharmaceuticals Holding Corp","year":"2023","unstructured":"Tonix Pharmaceuticals Holding Corp. TOSYMRA\u00ae (sumatriptan). Full Prescribing Information. Maple Grove (MN): Upsher-Smith Laboratories, LLC; 2023."},{"key":"e_1_3_5_65_1","unstructured":"US Food & Drug Administration. Drug approval package: Tosymra. 2019 [cited 2025 Jul 17]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/210884Orig1s000TOC.cfm"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0740-3"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1384"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17041"},{"key":"e_1_3_5_69_1","volume-title":"neffy (epinephrine nasal spray). Full prescribing information","author":"ARS Pharmaceuticals, Inc","year":"2025","unstructured":"ARS Pharmaceuticals, Inc. neffy (epinephrine nasal spray). Full prescribing information. San Diego (CA): ARS Pharmaceuticals, Inc.; 2025."},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060811"},{"key":"e_1_3_5_71_1","unstructured":"US Food and Drug Administration. NDA 214697 multi-discipinary review and evaluation. 2024 [cited 2025 Aug 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/214697Orig1s000MultidisciplineR.pdf"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.02.038"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.11.006"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.24m15665"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2010.01.013"},{"key":"e_1_3_5_76_1","first-page":"58","article-title":"Highly bioavailable nasal calcitonin - potential for expanded use in analgesia","volume":"10","author":"Maggio E","year":"2010","unstructured":"Maggio E, Meezan E, Ghambeer DKS, et al. Highly bioavailable nasal calcitonin - potential for expanded use in analgesia. Drug Delivery Technol. 2010;10:58\u201363.","journal-title":"Drug Delivery Technol"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.41.26820"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M204166200"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.12.039"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-010-9226-7"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123957"},{"key":"e_1_3_5_82_1","unstructured":"Madden S. Nasal delivery - improving nasal drug delivery with permeation enhancing technology. 2022 [cited 2026 Feb 19]. Available from: https:\/\/drug-dev.com\/nasal-delivery-improving-nasal-drug-delivery-with-permeation-enhancing-technology\/"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01486.x"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17385"},{"key":"e_1_3_5_85_1","first-page":"59","article-title":"Emerging trends in nasal spray development: tools for future success","volume":"16","author":"Thurston G","year":"2024","unstructured":"Thurston G, Rubino A. Emerging trends in nasal spray development: tools for future success. Int Pharm Ind. 2024;16:59\u201361.","journal-title":"Int Pharm Ind"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.01.053"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-025-00308-5"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12296"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.10.022"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2013.790887"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2007.06.012"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.05.011"},{"key":"e_1_3_5_93_1","unstructured":"US Food & Drug Administration. FDA approved second over-the-counter naloxone nasal spray product [news release]. 2023 [cited 2026 Feb 19]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-second-over-counter-naloxone-nasal-spray-product"},{"key":"e_1_3_5_94_1","unstructured":"Bayer. Astepro\u00ae allergy first and only steroid-free antihistamine nasal spray now available over-the-counter. 2022 [cited 2026 May 11]. Available from: https:\/\/bayer2019tf.q4web.com\/news\/news-details\/2022\/Astepro-Allergy-First-and-Only-Steroid-Free-Antihistamine-Nasal-Spray-Now-Available-Over-the-Counter\/default.aspx"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.4283"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-020-00891-5"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14977"},{"key":"e_1_3_5_98_1","volume-title":"NARCAN\u00ae (naloxone hydrochloride). Full Prescribing Information","author":"Adapt Pharma Inc","year":"2020","unstructured":"Adapt Pharma Inc. NARCAN\u00ae (naloxone hydrochloride). Full Prescribing Information. Plymouth Meeting (PA): Adapt Pharma, Inc.; 2020."},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1312"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-026-00418-4"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics10040172"}],"container-title":["Expert Opinion on Drug Delivery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2026.2713668","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17425247.2026.2713668","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17425247.2026.2713668","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:06:44Z","timestamp":1790870804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17425247.2026.2713668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":99,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,3]]}},"alternative-id":["10.1080\/17425247.2026.2713668"],"URL":"https:\/\/doi.org\/10.1080\/17425247.2026.2713668","relation":{},"ISSN":["1742-5247","1744-7593"],"issn-type":[{"value":"1742-5247","type":"print"},{"value":"1744-7593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iedd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}